Crescent Biopharma (NASDAQ:CBIO) Insider Ellie Eunkyung Im Sells 623 Shares of Stock

Crescent Biopharma, Inc. (NASDAQ:CBIO) insider Ellie Im sold 623 shares of Crescent Biopharma stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $17.90, for a total value of $11,151.70. Following the transaction, the insider owned 21,446 shares in the company, valued at $383,883.40. This trade represents a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ellie Eunkyung Im also recently made the following trade(s):

• On Monday, June 22nd, Ellie Im sold 1,219 shares of Crescent Biopharma stock. The stock was sold at an average price of $17.99, for a total transaction of $21,929.81.

Crescent Biopharma Price Performance

Shares of NASDAQ CBIO opened at $16.89 on Friday. The stock has a market cap of $627.29 million, a PE ratio of -2.51 and a beta of 1.24. Crescent Biopharma, Inc. has a 1 year low of $8.72 and a 1 year high of $27.41. The firm has a fifty day moving average price of $17.12 and a 200-day moving average price of $17.43.

Crescent Biopharma (NASDAQ:CBIO) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.74). On average, research analysts expect that Crescent Biopharma, Inc. will post -2.91 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on CBIO shares. Wedbush reiterated an “outperform” rating and issued a $27.00 target price on shares of Crescent Biopharma in a research report on Monday, September 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Crescent Biopharma in a report on Friday, August 7th. HC Wainwright reissued a “neutral” rating on shares of Crescent Biopharma in a report on Thursday, July 16th. Finally, TD Cowen upgraded shares of Crescent Biopharma to a “strong-buy” rating in a research report on Monday, August 24th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.60.

Institutional Investors Weigh In On Crescent Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in CBIO. Legal & General Group Plc purchased a new stake in Crescent Biopharma during the second quarter worth $38,000. OMERS ADMINISTRATION Corp boosted its stake in shares of Crescent Biopharma by 53.4% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 17,800 shares of the biopharmaceutical company’s stock worth $327,000 after acquiring an additional 6,200 shares in the last quarter. Opaleye Management Inc. grew its position in shares of Crescent Biopharma by 0.5% during the 2nd quarter. Opaleye Management Inc. now owns 1,319,351 shares of the biopharmaceutical company’s stock valued at $23,748,000 after acquiring an additional 6,736 shares during the period. Cannon Global Investment Management LLC purchased a new position in shares of Crescent Biopharma in the 1st quarter valued at about $187,000. Finally, Persistent Asset Partners Ltd acquired a new position in Crescent Biopharma in the 2nd quarter worth about $197,000. Institutional investors and hedge funds own 75.19% of the company’s stock.

Key Stories Impacting Crescent Biopharma

Here are the key news stories impacting Crescent Biopharma this week:

• Neutral Sentiment: CEO Joshua Brumm, COO Jonathan McNeill, CFO Richard Scalzo, and other insiders collectively sold 16,726 shares worth approximately $285,501 between September 16 and September 18. The sales reduced individual holdings by roughly 0.5% to 3.2%, but insiders continued to retain meaningful positions. SEC insider transaction filing
• Neutral Sentiment: All reported transactions were executed under pre-arranged Rule 10b5-1 trading plans and were described as sales to cover tax-withholding obligations tied to vested equity awards. That reduces the likelihood that the transactions represent a change in management’s outlook, although the aggregate selling may still weigh modestly on sentiment. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by senior executives—including the CEO and COO—could be viewed as a near-term supply or sentiment overhang. However, the relatively small percentage reductions and tax-related rationale make this a limited negative signal rather than a clear indication of weakening business prospects. SEC insider transaction filing

Crescent Biopharma Company Profile

Crescent Biopharma, Inc (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships.